We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Synthetic Virus Designed to Enhance Delivery of New Generation of Pharmaceutical Agents

By LabMedica International staff writers
Posted on 10 Sep 2014
Print article
Image: Design of the minimal viral coat protein C-Sn-B (Photo courtesy of Wageningen University).
Image: Design of the minimal viral coat protein C-Sn-B (Photo courtesy of Wageningen University).
Dutch scientists have effectively developed an artificial virus that may be used for the delivery of a new generation of pharmaceutical agents, consisting of large biomolecules, by packaging them in a natural manner and delivering them to diseased cells. The artificial virus was developed according to a new theoretic determination of how viruses work, according to the researchers.

The findings were published in the August 31, 2014, issue of the journal Nature Nanotechnology. Specifically, the researchers, from Wageningen University (The Netherlands), along with colleagues from the University of Leiden (The Netherlands), Eindhoven University of Technology (The Netherlands), and Radboud University Nijmegen (The Netherlands) think that the artificial virus technology could be useful for gene therapy.

Standard drugs consist of comparatively small molecules that typically arrive at the desired location without too much difficulty. This is more difficult for newer types of drugs that are being developed; these are comprised of large biomolecules such as proteins and genetic material (i.e., DNA and RNA). For example, to use DNA in gene therapy, the molecule must be delivered to diseased cells in its totality to be effective. However, DNA is inherently incapable of penetrating cells and is rapidly degraded. Therefore natural viruses that have been rendered harmless are used as so-called vectors. These can enter cells efficiently and deliver the therapeutic DNA or RNA molecules.

However, the process of rendering natural viruses harmless still requires improvement. Unwanted side effects have been a hurdle. Therefore, research is also being conducted into alternative virus-like vectors based on synthetic molecules. Regrettably, these have been less effective because it is difficult to precisely duplicate the many behaviors used by viruses. A first important step in mimicking viruses is the effective packaging of individual DNA molecules with a protective coat of smaller molecules. This sounds easier than it is, the researchers reported. Up to now, packing individual DNA molecules with a protective coating of synthetic molecules has not yet been accomplished.

The researchers decided to design and construct artificial viral coat proteins, instead of using synthetic chemistry to coat individual DNA molecules. As part of their study, they used recent theoretic insights into the key aspects of the process of packaging genetic material by natural viral coat proteins. The researchers converted each of these key features into various protein blocks with simple structures. The amino acid sequence of the protein blocks was inspired by natural proteins such as collagen and silk. Artificial viral coat proteins designed in this manner were produced using the natural processes of yeast cells. When the proteins were combined with DNA, they spontaneously formed a highly protective protein coat around each DNA molecule, thus creating artificial viruses. The formation process of the artificial viruses is similar in many ways to that of natural viruses, such as the tobacco mosaic virus, which served as a model for the artificial virus.

This first generation of artificial viruses was found to be as effective as the current methods for delivering DNA to host cells based on synthetic molecules. But the great precision by which DNA molecules are packaged in the artificial virus offers many possibilities to now also build in other virus tricks, the researchers write. In the future, these techniques can hopefully lead to safe and effective approaches for delivering new generations of pharmaceuticals, especially in gene therapy. Moreover, these artificial viruses can also be developed for the many other applications in which viruses are now being used in fields such as biotechnology and nanotechnology.

The artificial viral proteins were designed and produced by scientists of Wageningen UR (University & Research Center). They worked in collaboration with colleagues from Eindhoven University of Technology and Leiden University, who provided contributions based on the theory of spontaneous formation of virus particles, and helped to visualize the resulting artificial virus particles, and partners from Radboud University Nijmegen, who assessed the penetration of the artificial virus particles into living cells.

Related Links:

Wageningen University
University of Leiden 
Radboud University Nijmegen 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: Molecular PCR-grade detection of Lyme bacteria right at the tick bite (Photo courtesy of En Carta Diagnostics)

Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes

Lyme disease, transmitted through tick bites, is a bacteria-caused illness that impacts 1.2 million individuals annually. The standard methods for diagnosing this disease include clinical examinations,... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more